Rib-X Pharmaceuticals (Rib-X) plans to enter into a Clinical Trials Agreement with the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
Reportedly, the purpose of the agreement is to advance the clinical development of an oral formulation of Rib-X’s novel fluoroquinolone delafloxacin, in the treatment of Neisseria gonorrhoeae.
Under the agreement, Rib-X is preparing to progress delafloxacin to phase 3 clinical trials for multiple indications.
Susan Froshauer, president and CEO of Rib-X, said: “The agreement with the NIAID will further support the broad clinical potential for our lead compound, delafloxacin, which has already demonstrated potent activity against a variety of resistant bacteria and has successfully completed three phase 2 trials.
“In recent years, gonococcal infections have become increasingly resistant to available antibiotic treatments and we look forward to collaborating with the team at NIAID in the coming months to evaluate possible alternative therapeutic options for such infections.”